Coloplast down 4% as UBS sees limited upside after guidance cut

Investing.com · Navamya Acharya · 2026-11-06 13:14 UTC

Coloplast down 4% as UBS sees limited upside after guidance cut

Investing.com -- Coloplast (CSE:COLOb) shares fell over 4% on Friday after UBS downgraded the Danish chronic care products maker to "neutral" from "buy", saying its valuation leaves little room for further upside following cuts to its medium-term growth and margin targets.

The broker said Coloplast trades at about a 20% premium to the broader medical technology sector, a valuation it considers justified and already reflected in its price target.

The premium is only slightly below its three-year average, which UBS said was consistent with slightly lower expected growth.

Read the full story at Investing.com · All coverage of this story